The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease
Open accessAbstract
In neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD) and prion diseases, deposits of aggregated disease-specific proteins are found. Oligomeric aggregates are presumed to be the key neurotoxic agent. Here we describe the novel oligomer modulator anle138b [3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole], an aggregation inhibitor we developed based on a systematic high-throughput screening campaign combined with medicinal chemistry optimization. In vitro, anle138b blocked the formation of pathological aggregates of prion protein (PrP(Sc)) and of α-synuclein (α-syn), which is deposited in PD and other synucleinopathies such as dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). Notably, anle138b strongly inhibited all prion strains tested including BSE-derived and human prions. Anle138b showed structure-dependent binding to pathological aggregates and strongly inhibited formation of pathological oligomers in vitro and in vivo both for prion protein and α-synuclein. Both in mouse models of prion disease and in three different PD mouse models, anle138b strongly inhibited oligomer accumulation, neuronal degeneration, and disease progression in vivo. Anle138b had no detectable toxicity at therapeutic doses and an excellent oral bioavailability and blood-brain-barrier penetration. Our findings indicate that oligomer modulators provide a new approach for disease-modifying therapy in these diseases, for which only symptomatic treatment is available so far. Moreover, our findings suggest that pathological oligomers in neurodegenerative diseases share structural features, although the main protein component is disease-specific, indicating that compounds such as anle138b that modulate oligomer formation by targeting structure-dependent epitopes can have a broad spectrum of activity in the treatment of different protein aggregation diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Genome-wide association study reveals genetic risk underlying Parkinson's disease
Simón-Sánchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., et al. (2009) · Nature Genetics · doi:10.1038/ng.487 · Cited by 1,751
Harper, J. D., & Lansbury, P. T. (1997) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.66.1.385 · Cited by 1,652
Caughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650 · cited 1×
“Moreover, we could show in vitro that anle138b also inhibited generation of pathological α-syn oligomers that formed ion-permeable pores in lipid membranes, a potentially neurotoxic effector species in α-syn-related neurodegenerative diseases [11, 38, 40, 55] (Fig.”
BackgroundInclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein
Desplats, P., Lee, H.-J., Bae, E.-J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., Masliah, E., & Lee, S.-J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903691106 · Cited by 1,485
Reconstitution of Cell Membrane Structure in vitro and its Transformation into an Excitable System
MUELLER, P., RUDIN, D. O., TI TIEN, H., & WESCOTT, W. C. (1962) · Nature · doi:10.1038/194979a0 · Cited by 1,404
Prion Diseases of Humans and Animals: Their Causes and Molecular Basis
Collinge, J. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.519 · Cited by 1,344
Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding
Saborio, G. P., Permanne, B., & Soto, C. (2001) · Nature · doi:10.1038/35081095 · Cited by 1,310
Amyloid pores from pathogenic mutations
Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T., & Lansbury, P. T. (2002) · Nature · doi:10.1038/418291a · Cited by 1,289
Eight prion strains have PrPSc molecules with different conformations
Safar, J., Wille, H., Itri, V., Groth, D., Serban, H., Torchia, M., Cohen, F. E., & Prusiner, S. B. (1998) · Nature Medicine · doi:10.1038/2654 · Cited by 1,245
Luk, K. C., Kehm, V. M., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M. Y. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112457 · Cited by 1,100
Amyloid Fibrils of the HET-s(218–289) Prion Form a β Solenoid with a Triangular Hydrophobic Core
Wasmer, C., Lange, A., Van Melckebeke, H., Siemer, A. B., Riek, R., & Meier, B. H. (2008) · Science · doi:10.1126/science.1151839 · Cited by 998
The diagnosis of Parkinson’s disease
Tolosa, E., Wenning, G., & Poewe, W. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70285-4 · Cited by 902
A highly reproducible rotenone model of Parkinson's disease
Cannon, J. R., Tapias, V., Na, H. M., Honick, A. S., Drolet, R. E., & Greenamyre, J. T. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.01.016 · Cited by 795
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs
Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715
Wadsworth, J., Joiner, S., Hill, A., Campbell, T., Desbruslais, M., Luthert, P., & Collinge, J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05403-4 · Cited by 693
Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease
Korth, C., May, B. C. H., Cohen, F. E., & Prusiner, S. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161274798 · Cited by 673
Protein Aggregation in the Brain: The Molecular Basis for Alzheimer’s and Parkinson’s Diseases
Irvine, G. B., El-Agnaf, O. M., Shankar, G. M., & Walsh, D. M. (2008) · Molecular Medicine · doi:10.2119/2007-00100.irvine · Cited by 550
Fornai, F., Schlüter, O. M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., Lazzeri, G., Busceti, C. L., Pontarelli, F., Battaglia, G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409713102 · Cited by 526
Pan-Montojo, F., Anichtchik, O., Dening, Y., Knels, L., Pursche, S., Jung, R., Jackson, S., Gille, G., Spillantini, M. G., Reichmann, H., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008762 · Cited by 524
Self-citationResolving controversies on the path to Alzheimer's therapeutics
Selkoe, D. J. (2011) · Nature Medicine · doi:10.1038/nm.2460 · Cited by 494
In silico prediction of blood–brain barrier permeation
Clark, D. E. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02827-7 · Cited by 483
Small-molecule conversion of toxic oligomers to nontoxic β-sheet–rich amyloid fibrils
Bieschke, J., Herbst, M., Wiglenda, T., Friedrich, R. P., Boeddrich, A., Schiele, F., Kleckers, D., Lopez del Amo, J. M., Grüning, B. A., Wang, Q., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.719 · Cited by 445
Karpinar, D. P., Balija, M. B. G., Kügler, S., Opazo, F., Rezaei‐Ghaleh, N., Wender, N., Kim, H., Taschenberger, G., Falkenburger, B. H., Heise, H., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.257 · Cited by 432
Self-citationPan-Montojo, F., Schwarz, M., Winkler, C., Arnhold, M., O'Sullivan, G. A., Pal, A., Said, J., Marsico, G., Verbavatz, J.-M., Rodrigo-Angulo, M., et al. (2012) · Scientific Reports · doi:10.1038/srep00898 · Cited by 405
Self-citationCommon structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis
Glabe, C. G., & Kayed, R. (2006) · Neurology · doi:10.1212/01.wnl.0000192103.24796.42 · Cited by 367
Neumann, M., Kahle, P. J., Giasson, B. I., Ozmen, L., Borroni, E., Spooren, W., Müller, V., Odoy, S., Fujiwara, H., Hasegawa, M., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15777 · Cited by 355
Self-citationProtein Misfolding and Neurodegeneration
Soto, C., & Estrada, L. D. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.56 · Cited by 352
Mallucci, G. R., White, M. D., Farmer, M., Dickinson, A., Khatun, H., Powell, A. D., Brandner, S., Jefferys, J. G. R., & Collinge, J. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.005 · Cited by 266
A systematic review of prion therapeutics in experimental models
Trevitt, C. R. (2006) · Brain · doi:10.1093/brain/awl150 · Cited by 263
Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial
Collinge, J., Gorham, M., Hudson, F., Kennedy, A., Keogh, G., Pal, S., Rossor, M., Rudge, P., Siddique, D., Spyer, M., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70049-3 · Cited by 262
Are synucleinopathies prion-like disorders?
Angot, E., Steiner, J. A., Hansen, C., Li, J.-Y., & Brundin, P. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70213-1 · Cited by 251
Bieschke, J., Giese, A., Schulz-Schaeffer, W., Zerr, I., Poser, S., Eigen, M., & Kretzschmar, H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5468 · Cited by 240
Self-citationSingle Particle Characterization of Iron-induced Pore-forming α-Synuclein Oligomers
Kostka, M., Högen, T., Danzer, K. M., Levin, J., Habeck, M., Wirth, A., Wagner, R., Glabe, C. G., Finger, S., Heinzelmann, U., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709634200 · Cited by 226
Self-citationNeurotoxic protein oligomers — what you see is not always what you get
Bitan, G., Fradinger, E. A., Spring, S. M., & Teplow, D. B. (2005) · Amyloid · doi:10.1080/13506120500106958 · Cited by 221
Protease-Sensitive Scrapie Prion Protein in Aggregates of Heterogeneous Sizes
Salit Tzaban, Friedlander, G., Schonberger, O., Horonchik, L., Yedidia, Y., Shaked, G., Gabizon, R., & Taraboulos, A. (2002) · Biochemistry · doi:10.1021/bi025958g · Cited by 213
Cell‐free propagation of prion strains
Castilla, J., Morales, R., Saá, P., Barria, M., Gambetti, P., & Soto, C. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.181 · Cited by 191
Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses
Connelly, S., Choi, S., Johnson, S. M., Kelly, J. W., & Wilson, I. A. (2010) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2009.12.009 · Cited by 176
Neuronal Cell Death in Scrapie‐Infected Mice Is Due to Apoptosis
Giese, A., Groschup, M. H., Hess, B., & Kretzschmar, H. A. (1995) · Brain Pathology · doi:10.1111/j.1750-3639.1995.tb00597.x · Cited by 164
Self-citationScrapie strains maintain biological phenotypes on propagation in a cell line in culture
Birkett, C. R., Hennion, R. M., Bembridge, D. A., Clarke, M. C., Chree, A., Bruce, M. E., & Bostock, C. J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.13.3351 · Cited by 153
Pfeifer, A., Eigenbrod, S., Al-Khadra, S., Hofmann, A., Mitteregger, G., Moser, M., Bertsch, U., & Kretzschmar, H. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29236 · Cited by 149
Self-citation2-Aminothiazoles as Therapeutic Leads for Prion Diseases
Gallardo‐Godoy, A., Gever, J. R., Fife, K. L., Silber, B. M., Prusiner, S. B., & Renslo, A. R. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101250y · Cited by 142
Discovery of 2-Aminothiazoles as Potent Antiprion Compounds
Ghaemmaghami, S., May, B. C. H., Renslo, A. R., & Prusiner, S. B. (2009) · Journal of Virology · doi:10.1128/jvi.02145-09 · Cited by 136
Autocatalytic self-propagation of misfolded prion protein
Bieschke, J., Weber, P., Sarafoff, N., Beekes, M., Giese, A., & Kretzschmar, H. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404650101 · Cited by 123
Self-citationLamberto, G. R., Binolfi, A., Orcellet, M. L., Bertoncini, C. W., Zweckstetter, M., Griesinger, C., & Fernández, C. O. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902603106 · Cited by 113
Self-citationGadad, B. S., Britton, G. B., & Rao, K. S. J. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110182 · Cited by 110
Nosology of Parkinson’s Disease: Looking for the Way Out of a Quackmire
Forman, M. S., Lee, V. M. ‐., & Trojanowski, J. Q. (2005) · Neuron · doi:10.1016/j.neuron.2005.07.021 · Cited by 90
Schmidt, F., Levin, J., Kamp, F., Kretzschmar, H. A., Giese, A., & Bötzel, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042545 · Cited by 86
Self-citationHüls, S., Högen, T., Vassallo, N., Danzer, K. M., Hengerer, B., Giese, A., & Herms, J. W. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07254.x · Cited by 81
Self-citationBertsch, U., Winklhofer, K. F., Hirschberger, T., Bieschke, J., Weber, P., Hartl, F. U., Tavan, P., Tatzelt, J., Kretzschmar, H. A., & Giese, A. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7785-7791.2005 · Cited by 66
Self-citationSingle particle detection and characterization of synuclein co-aggregation
Giese, A., Bader, B., Bieschke, J., Schaffar, G., Odoy, S., Kahle, P. J., Haass, C., & Kretzschmar, H. A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.025 · Cited by 58
Self-citationTwo Different Binding Modes of α-Synuclein to Lipid Vesicles Depending on its Aggregation State
Högen, T., Levin, J., Schmidt, F., Caruana, M., Vassallo, N., Kretzschmar, H. A., Bötzel, K., Kamp, F., & Giese, A. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.01.059 · Cited by 44
Self-citationGayrard, V., Picard‐Hagen, N., Viguié, C., et al. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706072 · Cited by 39
Prusiner, S. B., Garfin, D. E., Cochran, S. P., McKinley, M. P., Groth, D., Hadlow, W. J., Race, R., & Eklund, C. M. (1980) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1980.tb03693.x · Cited by 37
Prerequisites to launch neuroprotective trials in Parkinson's disease: An industry perspective
Streffer, J. R., Grachev, I. D., Fitzer‐Attas, C. J., Gomez‐Mancilla, B., Boroojerdi, B., Bronzova, J., Ostrowitzki, S., Victor, S. J., da Fontoura, P. P., & Alexander, R. (2012) · Movement Disorders · doi:10.1002/mds.25017 · Cited by 23
Thompson, M. J., Louth, J. C., Ferrara, S. J., Jackson, M. P., Sorrell, F. J., Cochrane, E. J., Gever, J. R., Baxendale, S., Silber, B. M., Roehl, H. H., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.06.013 · Cited by 23
Cited by
Calabresi, P., Mechelli, A., Natale, G., Volpicelli-Daley, L., Di Lazzaro, G., & Ghiglieri, V. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-05672-9 · Cited by 817
Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors
Klingelhoefer, L., & Reichmann, H. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.197 · Cited by 598
Dehay, B., Bourdenx, M., Gorry, P., Przedborski, S., Vila, M., Hunot, S., Singleton, A., Olanow, C. W., Merchant, K. M., Bezard, E., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00006-x · Cited by 529
Current and experimental treatments of Parkinson disease: A guide for neuroscientists
Oertel, W., & Schulz, J. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13750 · Cited by 369
Ji, C. H., Kim, H. Y., Lee, M. J., Heo, A. J., Park, D. Y., Lim, S., Shin, S., Ganipisetti, S., Yang, W. S., Jung, C. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28520-4 · Cited by 350
Metadata
- Authors
- Wagner, J., Ryazanov, S., Leonov, A., Levin, J., Shi, S., Schmidt, F., Prix, C., Pan-Montojo, F., Bertsch, U., Mitteregger-Kretzschmar, G., Geissen, M., Eiden, M., Leidel, F., Hirschberger, T., Deeg, A. A., Krauth, J. J., Zinth, W., Tavan, P., Pilger, J., Zweckstetter, M., Frank, T., Bähr, M., Weishaupt, J. H., Uhr, M., Urlaub, H., Teichmann, U., Samwer, M., Bötzel, K., Groschup, M., Kretzschmar, H., Griesinger, C., & Giese, A.
- Venue
- Acta Neuropathologica
- Published
- 2013-04-19
- Volume
- 125
- Issue
- 6
- Pages
- 795-813
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2034075546
- Cited by
- 457
- References
- 59
- FWCI
- 9.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.